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Abstract 
The presence of inflammatory cells and MPO (myeloperoxidase) in the arterial wall after 
vascular injury could increase neointima formation by modification of phospholipids. This 
study investigates how these phospholipids, in particular oxidized and chlorinated species, are 
altered within injured vessels and how they affect VSMC (vascular smooth muscle cell) 
remodeling processes. Vascular injury was induced in C57BL/6 mice and high fat fed ApoE-/- 
mice by wire denudation and ligation of the left carotid artery. Neointimal and medial 
composition was assessed using immunohistochemistry and electrospray mass spectrometry. 
Primary rabbit aortic SMCs were utilized to examine the effects of modified lipids on VSMC 
proliferation, viability and migration at a cellular level. Neointimal area, measured as intima-
to-media ratio was significantly larger in wire-injured ApoE-/- mice (3.62 ± 0.49 vs. 0.83 ± 0.25 
in C57BL/6 mice, n=3) and there was increased oxidized LDL (oxLDL) infiltration and 
elevated plasma MPO levels. Relative increases in lysophosphatidylcholines and unsaturated 
phosphatidylcholines were also observed in wire-injured ApoE-/- carotid arteries. Chlorinated 
lipids had no effect on VSMC proliferation, viability or migration while chronic incubation 
with oxidized phospholipids stimulated proliferation in the presence of fetal calf serum (154.8 
± 14.2% of viable cells at 1 µM PGPC vs. control, n=6). In conclusion, ApoE-/- mice with an 
inflammatory phenotype develop more neointima in wire-injured arteries and accumulation of 
oxidized lipids in the vessel wall may propagate this effect  
3 
 
Abbreviations: 
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INTRODUCTION 
Revascularization procedures such as balloon angioplasty and stenting often result in 
neointimal hyperplasia in patients. This can be considered an exaggerated form of wound 
healing characterized by luminal (re)narrowing due to smooth muscle hyperplasia and rapid 
vascular remodeling of the instrumented vessel [1]. The formation of neointima is a complex 
and multifactorial process, but excessive VSMC (vascular smooth muscle cell) proliferation 
and migration, inflammation and the production of large amounts of ECM (extracellular 
matrix) are all involved [2]. 
Inflammation appears to be pivotal in driving neointima formation. In a rabbit model of balloon 
injury, there is early upregulation of leukocyte adhesion molecules on the injured vessel with 
increased inflammatory cell adhesion and transmigration [3]. There is also evidence of 
sustained inflammation, with inflammatory cells remaining in close proximity to the stent struts 
up to 28 days after placement [4]. In the mouse wire injury model, increased leukocyte adhesion 
to injured vessels is observed ex vivo up to 28 days following surgery [5]. The importance of 
circulating inflammatory cells was demonstrated in neutropenic rabbits, which had a 
significantly reduced extent of neointima at 28 days [6]. ApoE-/- mice (deficient in 
apolipoprotein E) are hyperlipidemic and demonstrate greater neointima formation following 
vascular injury induced by either wire denudation [7] or ex vivo aortic stenting and 
interpositional grafting [8]. ApoE-/- mice also show increased inflammatory cell adhesion to 
the injured carotid artery intima and, intriguingly, total plasma cholesterol correlated with 
neointima formation [7]. However, what remains to be determined is the role that modified 
lipids present in the vessel wall play in mediating the enhanced neointima formation in 
hyperlipidemic mice. 
Modification of LDL (low density lipoproteins) and formation of oxidized phospholipids 
contributes to the pathophysiology of atherosclerosis [9]. The phagocytic enzyme MPO 
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(myeloperoxidase) catalyzes the production of HOCl (hypochlorous acid) from hydrogen 
peroxide and chloride anions [10] and can cause chlorination of phospholipids [11]. The active 
form of MPO as well as HOCl-modified LDL are present in human atherosclerotic plaques [12, 
13] and correlate with an increase in the intima-to-media ratio in human iliac arteries [14]. 
Phospholipid chlorohydrins have a multitude of biological effects [15, 16]. Their high polarity 
can disrupt cell membranes and cause toxicity in myeloid and endothelial cells [17, 18] and 
can also induce leukocyte adhesion by upregulation of adhesion molecules [19]. 
Lysophosphatidylcholine-chlorohydrins have been detected in human atherosclerotic vessels 
with a 60-fold increase in plaques compared to healthy tissue [20], and fatty acid chlorohydrins 
have been found at high levels in the plasma of patients with acute pancreatitis [21]. Other 
chlorinated species such as 2-ClHDA (2-chlorohexadecanal) are produced by the action of 
MPO on plasmalogens [22] and have also been detected in human atherosclerotic plaques [23]. 
Oxidized phospholipids, such as oxidized PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-
phosphocholine) and its constituents, POVPC (1-palmitoyl-2-oxovaleroyl-sn-glycero-3-
phosphocholine) and PGPC (1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine), increase 
expression of pro-inflammatory genes in endothelial cells [24] and participate in the phenotypic 
switching of VSMCs that occurs following injury [25]. PAPC also induces monocyte adhesion 
and inflammation in atherosclerotic mice in vivo [26]. Several studies, including some 
conducted in vivo, have demonstrated that oxidized phospholipids can influence many of the 
processes involved in vascular remodeling such as VSMC proliferation, migration and 
extracellular matrix production [27-30]. 
 
In this study we used a mouse model of vascular injury in normal and hyperlipidemic ApoE-/- 
mice to generate vessels containing neointima. By comparing the lipid profile in the injured 
and contralateral uninjured carotid arteries, we were able to study how the presence of modified 
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phospholipids changes in an injured artery with neointima and how plasma hyperlipidemia 
influences this. We then studied the effects of some oxidized and chlorinated lipids known to 
be present in oxLDL (oxidized LDL) on cultured VSMCs, to assess whether the change in lipid 
profile observed in injured arteries could drive the main processes involved in neointima 
formation. 
 
MATERIALS AND METHODS 
 
Animals 
All experiments were performed in accordance with the United Kingdom Animals (Scientific 
Procedure) Act of 1986. Weight-matched C57BL/6 and ApoE-/- mice (22-29 g) were 8 to 10 
weeks of age at the start of the surgical procedure. Mice were maintained on 12 hour cycles of 
light and dark and at ambient temperature. C57BL/6 mice were fed a standard chow diet while 
ApoE-/- mice commenced a high fat diet (21% lard and 0.15% cholesterol, SDS, Essex, U.K.) 
at 6 weeks of age and continued on this throughout the study period. 
 
Murine carotid artery injury model 
Mice were given preoperative analgesia (i.p. (intraperitoneal) buprenorphine; 0.1 mg/kg), 
antiplatelet therapy (i.p. dipyridamole; 2.5 mg) and saline (0.5 ml subcutaneously). Carotid 
injury was performed according to an adapted method previously described [5]. General 
anaesthesia was induced by inhalation of 3% isoflurane supplemented with oxygen and 
maintained at 1.5% isoflurane throughout the procedure. The LCA (left carotid artery) was 
exposed and the proximal end ligated. An incision was made and a nylon fishing line (external 
diameter 0.014 in) with a blunt, spherical tip was inserted and advanced down the vessel with 
a torquing motion to ensure endothelial damage. The artery was then ligated distal to the 
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incision site. Mice where the artery was ligated without the insertion of the nylon line were 
also investigated as ligation alone has been shown to result in formation of neointima [31]. 
After 14 days, mice were euthanized and carotid arteries harvested and either fixed and 
embedded in paraffin wax for histological examination or snap frozen for ESMS (electrospray 
mass spectrometry) analysis. 
 
Histological analysis 
Paraffin embedded LCA and RCA (right carotid arteries) were serially sectioned at 4 µm and 
stained with haematoxylin and eosin to visualize and quantify medial and neointimal areas. To 
investigate the presence of proliferating and apoptotic cells as well as identify VSMCs in the 
vessel wall, immunohistochemistry was utilized. Briefly, sections were rehydrated and 
antigens retrieved by microwave pressure cooking in citric acid. Endogenous peroxidase and 
non-specific binding was blocked prior to primary antibody incubation overnight at 4 oC. The 
primary antibodies were diluted in 1% (w/v) BSA in PBS and used at the following dilutions: 
αSMA (alpha smooth muscle actin), 1:200, active caspase 3, 1:50, Ki67, 1:100 and E06, 1:100. 
Secondary antibody (anti-rabbit IgG antibody; Vector Laboratories, U.K.) or, in the case of 
E06, anti-mouse IgG (Abcam, U.K.) was added for 1 hour at room temperature before DAB 
chromagen solution (3,3-diaminobenzidine and hydrogen peroxidase solution; Vector 
Laboratories, U.K.) was added for between 2-5 minutes to develop. Slides were then 
counterstained with haematoxylin, dehydrated and coverslipped. In all cases, a negative control 
where the primary antibody was omitted was run concurrently. Staining was visualized using 
a light microscope and analyzed using QCapture Pro 6.0 software. 
 
Measurement of plasma MPO 
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The MPO content of plasma from C57BL/6 and ApoE-/- mice was analyzed using a mouse 
MPO ELISA kit (Hycult Biotech Inc., Netherlands). Plasma samples were diluted 1 in 16 in 
dilution buffer and the assay was performed as per the manufacturer’s instructions. A standard 
curve ranging from 1.6 ng/ml to 100 ng/ml was included for each experiment. Absorbance 
values were measured spectrophotometrically at 450 nm using a SpectraMax® M2 microplate 
reader. 
 
ESMS of phospholipids extracted from vessels 
The lipid content of uninjured, ligated and wire-injured arteries was investigated using a 
modified version of the Bligh-Dyer procedure [32] for lipid extraction from vessels. Briefly, 
LCA and RCA were placed in methanol containing 100 µg/ml of butylated hydroxytoluene, 
vortexed and sonicated for 15 minutes. An equal volume of chloroform was then added, 
vortexed and left overnight at 4 oC. An aqueous layer of 0.88% (w/v) KCl was added to the 
mixture, vortexed and incubated at 4 oC for 20 minutes. The layers were separated by 
centrifugation (13800 x g for 1 minute) and the chloroform phase removed and dried under a 
steady flow of oxygen-free nitrogen gas. Dried lipid extracts were reconstituted in 20% (v/v) 
chloroform in methanol and then diluted in methanol. Samples were run in either positive- or 
negative-ion mode by direct infusion on a QTRAP® 5500 mass spectrometer (AB SCIEX, 
Warrington, U.K.). For analysis using positive-ion mode, samples were diluted in 1% (v/v) 
aqueous formic acid in methanol, giving a final dilution of the lipid extracts of 1 in 500 for 
LCA and 1 in 250 for RCA. Spectra, in the range of m/z 400-1000, were acquired for 2 minutes. 
Precursor ion scanning was performed for m/z 184.1 which is selective for PCs 
(phosphatidylcholines) and a neutral ion loss scan of 141.1 Da for PEs 
(phosphatidylethanolamines). For analysis using negative-ion mode, samples were diluted in 
10% (v/v) 5 mM ammonium acetate in methanol, giving a final dilution of the lipid extracts of 
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1 in 50 for LCA and 1 in 25 for RCA. Spectra, in the range of m/z 400-1000, were acquired for 
4 minutes. Neutral loss scan of 87.0 Da was performed for PSs (phosphatidylserines). Samples 
were analyzed by looking for consistent differences observed between spectra from different 
sample groups. 
 
Preparation of chlorinated lipids 
Native phospholipid (SOPC, 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine) and the 
oxidized lipids, PGPC and POVPC, were purchased from Avanti Polar Lipids (Alabama, 
U.S.A.). Formation of chlorohydrins was assessed by the loss of the native phospholipid and 
the addition of m/z 52 or 54 (differences being due to the pattern of the chloride isotope, either 
35Cl or 37Cl) to the native phospholipid which was seen in its sodiated form (an additional 22 
m/z to the value compared to the protonated form). 
The alpha-chloro fatty aldehyde, 2-ClHDA, was synthesized and provided by Professor 
Andrew R. Pitt (Aston University, U.K.) following an adapted method previously described 
[33]. Briefly, hexadecanol was oxidized to hexadecanal using pyridinium chlorochromate in 
oxygen-free CH2Cl2, followed by reaction with methanol and catalytic p-toluenesulfonic acid 
to form the dimethyl acetal. The dimethyl acetal was then α-chlorinated utilizing MnO2-
trimethylchlorosilane. 2-ClHDA was finally produced by refluxing the chloroacetal in 1:1 
trifluoroacetic acid:dichloromethane and purified by flash chromatography using silica eluting 
with 7:3 hexane:dichloromethane to give solid 2-ClHDA (17% overall yield). 
 
VSMC proliferation, viability and migration 
Ideally, the in vitro effects of chlorinated and oxidized lipids would have been tested in mouse 
VSMCs. However, in order to provide a sufficient quantity of VSMCs for all assays, rabbit 
aortic SMCs were utilized and grown from explants. Although derived from a different species, 
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this allowed us to test several oxidized and chlorinated lipids, several incubation times and a 
range of concentrations, which would not have been possible using mouse cells. Use of primary 
cells from explants also avoided the use of immortalised cell lines or use of cells at a high 
passage where features associated with VSMCs may have been lost. Briefly, aortae from male 
New Zealand white rabbits (2.5 to 3.5 kg body weight) were excised and cleaned of any 
connective tissue and fat. The outer and inner surface of the vessel was scraped, removing the 
adventitia and endothelium respectively. VSMCs were cultured in in 1:1 Waymouth’s MB 
752/1 and Ham’s F12 with GlutaMAX supplemented with 1% (v/v) penicillin-streptomycin 
solution and 10% (v/v) FCS (fetal calf serum) and used between passages 3 to 8. Cells were 
identified as VSMCs by positive immunofluorescent staining for αSMA (data not shown). All 
oxidized or chlorinated lipids were resuspended in serum-free VSMC medium at a 
concentration of 1x10-2 M by vortexing and sonicating before diluting to the required 
concentration for cell treatment. Under these conditions, the lipids form multilamellar vesicles 
rather than micelles or liposomes. 
 
The effect of modified lipids on cell proliferation was measured using a BrdU 
(bromodeoxyuridine) assay kit (Calbiochem, U.K.). Cells were seeded in 96 well plates at a 
density of 10,000 cells per well and quiesced in 0.1% (v/v) FCS-containing medium for 24 
hours. Cells were incubated with the chlorinated or oxidized lipids (1-100 µM) for either 2 
hours in 0.1% FCS-containing medium for acute experiments or, in the case of chronic 
exposure, for 24 hours in the presence of 10% FCS. VSMCs were then stimulated with 10% 
FCS-containing medium and addition of BrdU 24 hours prior to terminating the experiment. 
The assay was performed as per the manufacturer’s instructions and proliferation was detected 
using a spectrophotometric measurement of absorbance at dual wavelengths of 450 nm and 
540 nm using a SpectraMax M2 microplate reader. 
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Bioluminescent detection of cellular ATP using a ViaLight™ Plus kit (Lonza, Switzerland) 
was employed to determine cell viability after either 2 or 6 hours in 0.1% FCS-containing 
medium or 24 hours exposure to the modified lipids in the presence of FCS. This assay enables 
a comparison to be made between cells incubated under control conditions with those incubated 
with lipids. A reduction in total cellular ATP is indicative of a degree of cell apoptosis or 
necrosis though it cannot distinguish between the two. Cells were prepared as for the 
proliferation assay then lysis buffer was added to release cellular ATP. Following this, ATP 
Monitoring Reagent Plus containing luciferase was added to the lysed cells to catalyze the 
conversion of ATP and luciferin into emitted light. Luminescence was measured using a 
POLARstar OPTIMA microplate reader (BMG Labtech, Germany). 
Cell migration was measured using a CHEMICON® QCM chemotaxis cell migration assay 
containing an 8 µm pore membrane (Millipore, Watford, U.K.). Cells were quiesced in 0.1% 
FCS-containing medium for 24 hours prior to stimulation. For pretreatment experiments, cells 
were incubated for 2 hours with either the chlorinated or oxidized lipids then harvested and 
added at 30 000 cells/well to the top chamber in serum-free medium. 10% FCS-containing 
medium was utilized as the chemotactic agent in the lower chamber. After 24 hours, the 
remaining cells and media present in the upper chamber were aspirated and non-migrated cells 
were removed from the interior side of the insert. The membrane was then stained, placed in 
the extraction buffer and the absorbance measured at 560 nm using a SpectraMax M2 
microplate reader. For chronic experiments, the lipid was present in the top chamber for the 
full 24 hour stimulation period. 
 
Statistical analysis 
All results are expressed as mean ± SEM. Data were analyzed with GraphPad Prism 5.0 
software (California, U.S.A.) using either a one-way ANOVA followed by a Dunnett’s or two-
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way ANOVA followed by Bonferroni’s post hoc test as appropriate. In all cases, p<0.05 was 
considered statistically significant. 
 
RESULTS 
 
Extent of neointima formation in C57BL/6 and ApoE-/- mice 
Ligation of the LCA without wire injury resulted in formation of measurable neointima 
compared to the contralateral, uninjured RCA in both C57BL/6 and ApoE-/- mice (Figure 1A). 
There was significantly more neointima, measured as the intima-to-media ratio, present in 
injured ApoE-/- LCA compared to both injured C57BL/6 vessels and ligated ApoE-/- vessels 
(Figure 1B). Measurement of the external elastic lamina length revealed no difference in vessel 
circumference between groups and microscopic examination of ApoE-/- aortae revealed no 
atherosclerotic plaques (Figure 1A). However, ApoE-/- mice did display a generalized 
inflammation characterized by significantly increased plasma MPO compared to C57BL/6 
mice in both ligated and injured groups (Figure 1C) and a significantly increased spleen weight 
relative to total body weight (data not shown). Immunohistochemical analysis of neointima at 
14 days revealed no difference in the presence of VSMCs (αSMA; Figure 2A) or proliferating 
cells (Ki67; Figure 2B). Minimal staining for active caspase 3, a marker of apoptosis was found 
in all groups (Figure 2C). 
 
Presence of modified lipids in the arterial wall after acute vascular injury 
In the uninjured RCA, neither strain showed any positive staining for oxLDL using the E06 
antibody (Figure 3). In injured vessels, ApoE-/- mice had a greater abundance of oxLDL present 
compared to C57BL/6 mice where expression was lower and more variable (Figure 3). Using 
ESMS, the ratios of different phospholipids in uninjured, ligated and injured arteries from 
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C57BL/6 and ApoE-/- mice were studied. Some differences in lipid profile between C57BL/6 
and ApoE-/- carotid arteries were noted, but more importantly, the response to ligation and 
injury differed. Significantly higher relative levels of lysophosphatidylcholines were found in 
both ligated and injured ApoE-/- carotid arteries compared with the uninjured RCA while no 
change in lysophosphatidylcholines were seen in C57BL/6 mice after vascular injury (Figure 
4). Precursor ion scanning for m/z 184.1 displayed small elevations in the relative levels of 
PCs, m/z 734.9 (C32:0) in ligated and injured carotid arteries of C57BL/6 mice and m/z 810.9 
(C38:4) in ligated carotid arteries (Figure 4A and C). In ApoE-/- mice, m/z 734.9 (C32:0) was 
also relatively increased in ligated arteries, as was m/z 758.9 (C34:2) and 786.9 (C36:2) in both 
ligated and injured vessels compared to the uninjured RCA (Figure 4B and D). In comparison, 
there was a reduction in the relative levels of m/z 782.9 (C36:4) and 810.9 (C38:4) in injured 
ApoE-/- carotid arteries. No detectable changes were observed in chain-shortened PCs. PEs and 
PSs were present at considerably lower concentrations than PCs and there were no significant 
changes across the groups in either strain of mice (data not shown). 
 
Effect of modified lipids on VSMC remodeling processes 
As we found changes in lysophosphatidylcholines and other PCs in the injured vessel wall, and 
since raised plasma MPO may form modified lipids which could contribute to the greater 
neointima formation in ApoE-/- mice, we assessed the effect of selected chlorinated and 
oxidized lipids on VSMC remodeling processes. Following acute exposure (2 hours in 0.1% 
FCS-containing medium) neither the phospholipid chlorohydrin, SOPC ClOH nor the alpha-
chloro fatty aldehyde, 2-ClHDA had any effect on VSMC proliferation, viability or migration, 
even at concentrations as high as 100 µM (Figure 5). In contrast the oxidized lipids POVPC or 
PGPC caused a significant reduction in VSMC proliferation and viability at concentrations of 
25 µM (PGPC) or 50 µM (POVPC) and above. At lower, non-toxic concentrations neither 
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oxidized lipid affected VSMC migration (Figure 6). No morphological changes were observed 
following either chlorinated lipid treatment (Figure 5E); however, substantial cell death was 
evident after incubation with 50 µM of either oxidized phospholipid (Figure 6E). A longer 
incubation (6 hours in 0.1% FCS-containing medium) with SOPC ClOH caused a 
concentration-dependent reduction in VSMC viability at 100 µM, whereas 2-ClHDA had no 
effect (data not shown). As expected, 6 hours incubation with POVPC caused a dramatic 
reduction in VSMC viability (data not shown). 
Chronic incubation (24 hours in 10% FCS-containing medium) with SOPC ClOH or 2-ClHDA 
had no effect on VSMC proliferation, viability or migration (data not shown). Paradoxically, 
the decline in proliferation and viability seen after 2 hours treatment with POVPC was reversed 
with chronic incubation (Figure 7A-C) while PGPC significantly increased VSMC 
proliferation and viability (Figure 7B-D). However, both POVPC and PGPC caused a marked 
reduction in migration at the highest concentration studied (Figure 7F-G). No significant 
changes in morphology were observed with either treatment (Figure 7E). 
 
DISCUSSION 
 
Here we characterize for the first time the phospholipid content of the arterial wall of C57BL/6 
and ApoE-/- mice after wire injury. Increased neointima formation was observed in injured 
arteries in ApoE-/- mice, as well as elevated plasma MPO levels, increased oxLDL and an 
altered lipid profile in the arterial wall in comparison with C57BL/6 mice and also in 
comparison with the uninjured contralateral carotid artery. In addition, this study is the first to 
investigate the effects of chlorinated lipids on VSMC remodeling processes and highlight the 
divergent effects of chlorinated and oxidized lipid species. Chlorinated lipids had no effect on 
VSMC proliferation, viability or migration, whereas oxidized phospholipids caused a 
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concentration-dependent reduction in all of these VSMC remodeling processes, which was 
reversed in the presence of FCS. 
In this study, neointima formation was dramatically increased in injured ApoE-/- arteries 
compared to carotid ligation without injury, while no significant differences were observed in 
C57BL/6 mice. Increased neointima formation has previously been observed following both 
wire and balloon injuries in ApoE-/- mice [7, 34, 35] suggesting there is an increased 
susceptibility for neointima formation in atherosclerotic or hyperlipidemic mice. Elevated 
plasma MPO content could contribute to the enhanced inflammatory state of these mice and 
result in an increase in the production of reactive oxidants. Indeed, increased oxLDL was 
detected in the neointima of ApoE-/- mice, which may well have occurred through the 
heightened inflammation and/or MPO in the vessel wall after injury. Incubation of MPO and 
its product, HOCl, in a temporarily isolated carotid artery induced intimal and medial apoptosis 
which was followed by a proliferative response and neointima hyperplasia in a rat model [36]. 
In this study, only the plasma MPO was measured and therefore the level of MPO in the 
neointima is unknown. However, greater infiltration of inflammatory cells at the site of injury 
in ApoE-/- mice is likely to enhance the secretion of MPO in the developing neointima. 
MPO is a known route for producing both chlorinated and oxidized lipid species in vivo. Intact 
phospholipid chlorohydrins have yet to be observed in diseased vessels in vivo while 
lysophosphatidylcholine-chlorohydrins have been detected in human atherosclerotic vessels 
with a 60-fold increase in plaques compared to healthy tissue [20]. We observed a marked 
elevation in the relative levels of lysolipids at m/z 496.7 (lyso-palmitoyl PC) and 524.7 (lyso-
stearoyl PC) in ligated and injured ApoE-/- carotid arteries in comparison to the uninjured 
vessels and C57BL/6 mice. Lysophosphatidylcholine has previously been found to induce 
apoptosis in VSMCs and promote recruitment of monocytes [37, 38], which could lead to an 
exacerbated inflammatory response at the site of injury. The precursor ion scan for m/z 184.1 
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displayed an increase in relative abundance of unsaturated PCs such as m/z 758.9 (C34:2) and 
786.9 (C36:2) in ligated and injured LCA of ApoE-/- mice and a reduction in m/z 782.9 (C36:4) 
and 810.9 (C38:4). This suggests there is an increase in di-unsaturated species in ApoE-/- mice 
following vascular injury but a reduction in arachidonate-containing PCs in the injured arteries. 
These unsaturated PCs could then undergo modification by MPO leading to a further increase 
in modified lipids present at the site of injury. However, chain-shortened PCs were not 
detected, which could be due to low concentrations compared to their native phospholipids 
within these samples, or they may be metabolized or detoxified in vivo [39]. The high levels of 
plasma MPO in ApoE-/- mice suggests the concept of increased levels of HOCl and therefore 
of chlorinated lipids in the vessels, although without a more extensive investigation by LC-
MSMS and GCMS, and quantification of MPO within the vessel itself it is not possible to 
confirm this. 
The levels of modified lipids found in pathophysiological conditions have previously proved 
hard to quantify, owing to the limited availability of suitable controls and the large number of 
different structures present. A limitation of the present study is the lack of internal or external 
standards in the ESMS analysis. In this study, the sizes and weights of the arteries varied thus 
the lipid concentrations could not be accurately calculated. However, the amount of lipid 
present is likely to vary within the artery therefore, while standards may indicate the absolute 
concentration, all lipids should fluctuate depending on the total lipid content extracted. It 
should also be noted that ESMS is not a quantitative technique in itself, due to the different 
ionization efficiencies of lipid classes, therefore PC levels cannot be directly compared with 
PEs or PSs. However, all these differences should fluctuate concurrently between samples, thus 
it is valid to look for changes in relative intensities and patterns between samples. In areas of 
inflammation such as rheumatoid arthritis, the presence of OCl-, the anion present in HOCl, 
has been found to reach concentrations of up to 300 µM, due to the presence of neutrophils 
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releasing MPO [40]. The levels of oxidized phospholipids have also been found within the 
micromolar range in atherosclerotic plaques in both human and animal tissue [41-43]. 
Within this concentration range, chlorinated lipids were found to have little to no effect on 
VSMCs. The majority of work published previously has observed toxicity with incubation of 
chlorohydrins thought to be caused by disruption of the membrane due to their high polarity 
[17]. However, necrotic cell death has also been reported in endothelial cells and an increase 
in caspase 3 levels suggesting apoptosis in myeloid cells [18, 44]. The lack of cytotoxicity 
described in this study may be due to the different cell type used, as VSMCs could be more 
resistant to the effects of chlorohydrins than other cell types, or potential species differences. 
In contrast to chlorohydrins, very little is known about the actions of alpha-chloro fatty 
aldehydes as the few studies conducted focussed primarily on endothelial cells and nitric oxide 
biosynthesis [45, 46]. 2-ClHDA was thought to be an exciting prospect with its identification 
in atherosclerotic lesions in vivo; however, no effects were observed on the vascular 
remodeling processes examined in this study. 
In stark contrast, oxidized phospholipids caused a dramatic concentration-dependent reduction 
in VSMC proliferation and viability after 2 hours incubation. These lipids have been found to 
induce apoptotic signaling pathways by the activation of sphingomyelinase and, in particular, 
the acid form of the enzyme which is known to be involved in the earlier stages of apoptosis 
resulting in phosphorylation of MAPK and caspase 3 signaling [47, 48]. A biphasic response 
of oxidized phospholipids has been reported previously with proliferation occurring at low 
concentration and apoptosis predominating at high concentrations [27, 29]. In the present study, 
chronic incubation of oxidized phospholipids in the presence of FCS abolished cell death and 
induced an increase in proliferation and viability. This would suggest that the presence of serum 
phospholipases causes a breakdown of oxidized phospholipids into a product with anti-
apoptotic effects. This is in partial agreement with a previous study; however, the anti-
18 
 
proliferative nature of the lipids was still seen with the oxidized phospholipid treatment in the 
presence of FCS [28]. PGPC rather than POVPC had the greater effect in all our experiments, 
despite the fact that the latter has been suggested to be the more potent of the two truncated 
oxidation products of PAPC [28, 47]. However, recently PGPC has been reported to have a 
higher toxicity in cultured macrophages due to more efficient membrane blebbing in apoptotic 
cells [49]. 
Previous studies have found apoptosis to peak at about 24 hours after vascular injury while 
proliferation occurs later in the process, at around 4 days after injury [7, 36]. This correlates 
with the oxidized phospholipid data described in this study, where VSMC death was induced 
after a short incubation time of only 2 hours. Modified lipids could also be involved in the latter 
proliferative stages of vascular injury leading to the formation of neointima; however, this 
would be difficult to measure in vitro. Longer incubations would require medium containing 
growth supplements such as FCS which would lead to the breakdown of these lipids as shown 
in this study and by Fruhwirth et al, (2006). 
In conclusion, we have detected alterations in several modified lipids in ligated and wire-
injured carotid arteries from ApoE-/- mice compared to uninjured vessels and C57BL/6 
controls. These differences are likely to be a consequence of heightened inflammatory state in 
the plasma of hyperlipidemic ApoE-/- mice coupled with inflammatory cell infiltration 
following wire injury. Our in vitro data suggest that chlorinated lipids are unlikely to be 
involved in vascular smooth muscle remodeling processes which lead to neointima formation. 
However, incubation of oxidized lipids in the presence of FCS led to increased proliferation 
and accumulation of these species in the artery wall following injury and so they may be 
involved in propagating neointima formation. This hypothesis requires to be tested in vivo. 
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 Abnormal VSMC proliferation and migration contribute to restenosis in patients 
following revascularization techniques such as balloon angioplasty or stent 
implantation. MPO (myeloperoxidase) and modified lipids have been found to be vital 
mediators in the propagation of the inflammatory response and plaque formation, 
suggesting they could be viable targets in preventing restenosis. 
 The present study shows the altered phospholipid expression within the injured arterial 
wall of hyperlipidemic mice and elevated MPO levels. In addition, there were divergent 
effects of modified lipids on VSMC remodeling processes. 
 These findings suggest that changes in unsaturated phospholipids could be involved in 
initiating and maintaining VSMC remodeling processes which are critical in restenosis 
in patients and therefore could be targeted for future therapies. 
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FIGURE LEGENDS 
Figure 1 Effect of vascular injury on the intima-to-media ratio and plasma MPO 
levels in C57BL/6 and ApoE-/- mice. 
(A) Representative histological sections of RCA and LCA from ligated and injured C57BL/6 
and ApoE-/- mice using haematoxylin and eosin staining. Scale bar for LCA and RCA = 100 
µm, magnification x 10. Scale for aorta = 250 µm, magnification x 4. (B) Neointimal growth 
in LCA after vascular injury was assessed as the intima-to-media ratio. ‡‡p<0.01 vs. C57BL/6 
injured, ††p<0.01 vs. ApoE-/- ligated. Each bar represents the mean ± S.E.M. of 3 or 4 animals. 
(C) The MPO content of mouse plasma was measured using a mouse MPO ELISA kit. 
***p<0.001 vs. C57BL/6 ligated, ‡‡‡p<0.001 vs. C57BL/6 injured. Each bar represents the 
mean ± S.E.M. of six animals. 
 
Figure 2 Effect of vascular injury on smooth muscle, proliferative and apoptotic 
markers in C57BL/6 and ApoE-/- mice. 
Representative histological sections of injured LCA of C57BL/6 and ApoE-/- mice which were 
stained with (A) anti-αSMA, (B) anti-Ki67 and (C) anti-active caspase 3 then counterstained 
with haematoxylin. Positive immunoreactivity for αSMA, Ki67 or active caspase 3 was 
measured as a percentage of positive DAB staining divided by the neointimal area. Scale bar = 
100 µm, magnification x 10. Each bar represents mean ± S.E.M. of three animals. 
 
Figure 3 Detection of oxLDL in the carotid arteries of C57BL/6 and ApoE-/- mice. 
Representative histological sections of RCA and LCA of C57BL/6 (top) and ApoE-/- mice 
(bottom) which were stained with E06 to detect oxLDL. Scale bar = 100 µm, magnification x 
20 (left) or x 10 (right). 
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Figure 4 Effect of vascular injury on modified lipids present in the neointima and 
arterial wall of C57BL/6 and ApoE-/- mice. 
(A) Precursor ion scanning for m/z 184.1 by positive-ionization ESMS identified the 
distribution of PCs in uninjured RCA, ligated and injured LCA of C57BL/6 mice. Spectra 
shown are representative. The signal at m/z 564.0 was not identified as a phospholipid species 
and is thought to be a contaminant from the HPLC system. (B) Precursor ion scanning for m/z 
184.1 by positive-ionization ESMS identified the distribution of PCs in uninjured RCA, ligated 
and injured LCA of ApoE-/- mice. Spectra shown are representative. (C) Relative intensities of 
detected PCs as a percentage of the largest peak in C57BL/6 mice. *p<0.05, **p<0.01 and 
***p<0.001 vs. uninjured. Each bar represents the mean ± S.E.M. of three animals. (D) Relative 
intensities of detected PCs as a percentage of the largest peak in ApoE-/- mice. *p<0.05, 
**p<0.01 and ***p<0.001 vs. uninjured. Each bar represents the mean ± S.E.M. of three 
animals. 
 
Figure 5 Effect of acute treatment of chlorinated lipids on VSMC remodeling 
processes. 
VSMCs were incubated with 1-100 µM of SOPC ClOH or 2-ClHDA for 2 hours prior to 
stimulation with 10% FCS-containing medium. (A-B) VSMC proliferation was assessed by 
incorporation of BrdU. (C-D) Cell viability was measured by detection of cellular ATP. (E) 
Representative images of VSMCs treated with chlorinated lipids to visualize morphological 
changes. (F-G) Cell migration was measured using a chemotaxis assay. Each bar represents 
the mean ± S.E.M. of six animals and performed in triplicate. 
 
Figure 6 Effect of acute treatment of oxidized phospholipids on VSMC remodeling 
processes. 
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VSMCs were incubated with 1-100 µM of POVPC or PGPC for 2 hours prior to stimulation 
with 10% FCS-containing medium. (A-B) VSMC proliferation was assessed by incorporation 
of BrdU. (C-D) Cell viability was measured by detection of cellular ATP. (E) Representative 
images of VSMCs treated with oxidized phospholipids to visualize morphological changes. (F-
G) Cell migration was measured using a chemotaxis assay. *p<0.05, **p<0.01 and ***p<0.001 
vs. 10% FCS control. Each bar represents the mean ± S.E.M. of six animals and performed in 
triplicate. 
 
Figure 7 Effect of chronic incubation of oxidized phospholipids on VSMC 
remodeling processes. 
(A-B) VSMC proliferation was assessed by incorporation of BrdU. (C-D) Cell viability was 
measured by detection of cellular ATP. (E) Representative images of VSMCs treated with 
oxidized phospholipids to visualize morphological changes. (F-G) Cell migration was 
measured using a chemotaxis assay. *p<0.05 and ***p<0.001 vs. 10% FCS control. Each bar 
represents the mean ± S.E.M. of six animals and performed in triplicate. 
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SUMMARY STATEMENT 
Many patients have to undergo revascularization techniques following stent implantation due 
to neointima hyperplasia. The present study highlights a link between modified lipids and 
vascular smooth muscle remodeling processes, which are critical in this neointima formation. 
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